America’s Stem Cell Mess
By Josephine Johnston,
The Scientist
| 10. 13. 2010
[Opinion]
It’s hard not to feel sorry for American embryonic stem cell (ESC) researchers. Over the dozen years since the cells were first derived, they’ve been expected to meet federal rules that change with each president, research guidelines from the National Academy of Sciences as interpreted by their institutions, and separate requirements from state and private funders. While the extremely restrictive policies of the Bush administration caused a number of alternative funders to step up to the plate, each comes with its own rules, restrictions, and reporting requirements. Labs with a mix of federal and private funding are required to account for the monies separately, leading to the somewhat absurd practice of color-coding lab instruments and workspace so that nothing paid for with federal money is used to do something federal policies prohibit.
The picture brightened last year when President Obama lifted his predecessor’s restrictions, allowing the National Institutes of Health (NIH) to release new guidelines for an expanded ESC research program. But this August, a judge issued a preliminary injunction putting that entire program on hold. NIH has appealed the...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...